37 results on '"Baldi, Giacomo Giulio"'
Search Results
2. REGORAFENIB IN ADVANCED SOLITARY FIBROUS TUMOUR: RESULTS FROM AN EXPLORATORY PHASE II CLINICAL STUDY
3. The rare entity of gastrointestinal leiomyosarcomas: An Italian multicenter retrospective study in high‐volume referral centers
4. Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts
5. Trabectedin in advanced retroperitoneal well differentiated/dedifferentiated liposarcoma and leiomyosarcoma (TRAVELL): Results of a phase 2 study from Italian sarcoma group (ISG).
6. A Global CollaboRAtive Study of CIC-Rearranged, BCOR::CCNB3-Rearranged and Other Ultra-Rare Unclassified Undifferentiated Round Cell Sarcomas (GRACefUl)
7. EJSO educational Special issue from the TARPSWG - Standard medical treatment and new options in retroperitoneal sarcoma
8. Systemic Treatment in Advanced Phyllodes Tumor of the Breast: A Multi-Institutional European Retrospective Case-Series Analyses
9. Systemic Treatment in Advanced Phyllodes Tumor of the Breast: A Multi-institutional European Retrospective Case-series Analyses
10. Primary pleural epithelioid hemangioendothelioma: case report and review of the literature
11. Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid‐type fibromatosis
12. Regorafenib (R) in advanced solitary fibrous tumor (SFT): Results from an exploratory phase II clinical study.
13. First-Line Systemic Chemotherapy with Folfoxiri Followed by Radical Surgical Resection of Metastases for the Treatment of Unresectable Metastatic Colorectal Cancer Patients
14. In Reply
15. Extraskeletal Myxoid Chondrosarcoma: State of the Art and Current Research on Biology and Clinical Management
16. Pharmacokinetics, safety, and activity of trabectedin as first‐line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group
17. The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis
18. The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group
19. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors
20. Activity of hormonal treatment in uterine smooth muscle tumors of uncertain malignant potential (STUMP): A mono-institutional referral center experience in advanced disease.
21. Activity of chemotherapy in inflammatory myofibroblastic tumor (IMT): A retrospective analysis within the Italian Rare Tumours Network (RTR).
22. Activity of sirolimus in advanced epithelioid hemangioendothelioma (EHE): A retrospective analysis within the Italian Rare Tumor Network (RTR).
23. Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes
24. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone – Multicenter analysis outside clinical trial
25. Different View on Larynx Preservation Evidence-Based Treatment Recommendations
26. Case 2 – Lack of response to trastuzumab in a patient with metastatic gastric cancer progressing after extended response to MET inhibitor therapy
27. Managing pazopanib toxicity in the treatment of advanced soft tissue sarcoma
28. Use of first-line trabectedin in advanced leiomyosarcoma: a review of clinical data and future perspectives
29. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series
30. Denosumab in patients with resectable giant cell tumor of bone (GCTB): Effect on surgical downstaging in a “real world” experience.
31. Small-Bowel Neuroendocrine Tumor and Retroperitoneal Fibrosis: Efficacy of Octreotide and Tamoxifen
32. Safety of trabectedin (T) in elderly patients (pts) with advanced soft tissue sarcoma (STS).
33. Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options
34. Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen
35. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status
36. Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients
37. High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.